#lifescience industry

Triton Market Research presents the Global Companion Diagnostics Market report segmented by Consumer (Reference Laboratories, Pharmaceutical and Biopharmaceutical Companies, Other Consumers), Mechanism (Polymerase Chain Reaction, Next Generation Sequencing, In-Situ Hybridization, Immunohistochemistry, Other Mechanisms), Indicator (Neurology, Oncology, Infectious Disease, Other Indicators), Commodity (Software & Services, Assay Kits & Reagents), and Regional Outlook (Europe, Asia-Pacific, North America, Latin America, Middle East and Africa).

The report further discusses the Market Summary, Industry Outlook, Impact of COVID-19, Key Insights, Porter’s Five Forces Analysis, Market Attractiveness Index, Vendor Scorecard, Drivers, Challenges, Opportunities, Competitive Landscape, Research Methodology & Scope, Global Market Size, Forecasts & Analysis (2022-2028).

As per Triton’s research report, the global companion diagnostics market is estimated to witness growth at a CAGR of 12.84% during the forecast period 2022-2028.

A companion diagnostics device helps attain crucial data to efficiently match a drug or therapy. It is a personalized treatment that includes drug testing, clinical trials, and research.

Genome sequencing has emerged as a significant step in the gene therapy process. This has increased investments in next generation gene sequencing. Moreover, the rising research in the space is expected to promote the companion diagnostics market’s growth. Furthermore, the growing investments and research in precision medicine are also anticipated to elevate the demand for companion diagnostics tests, thereby opening new avenues for the studied market.

However, a weak reimbursement framework and common cases of leakage in oncology companion diagnostics restrict the companion diagnostics market’s growth.

Globally, the Asia-Pacific is expected to emerge as the fastest-growing region over the forecast period. The region is witnessing growth owing to the increasing development of precision medicine technology. Moreover, an initiative undertaken by regulatory authorities and the pharmaceutical industry to increase precision medicine development drives the demand for companion diagnostics tests. Above all, the increase in healthcare awareness and economic growth are expected to open new avenues for the companion diagnostics market.

Danaher Corporation, GE Healthcare, Roche Diagnostics, Arup Laboratories, Almac Group, Thermo Fisher Scientific, Genomic Health, Myriad Genetics, Illumina Inc, bioMerieux, Qiagen, Biocartis, Sysmex Corporation, Agilent, and Abbott Laboratories are leading companies in the companion diagnostics market.

Lifesciences

09, December 2022

According to the WHO, epilepsy is a chronic brain disorder that affects 50 million individuals, making it one of the most prevalent neurological conditions worldwide. It is estimated that with access to early detection and appropriate care, 70% of the population diagnosed with epilepsy may live seizure-free. According to our estimates, the global epilepsy devices market was valued at $669.73 million in 2021 and is expected to reach $1157.58 million by 2028, growing at a CAGR of 8.16% during the forecast period 2022-2028.

Government institutions worldwide are focused on starting initiatives to create innovative epilepsy devices with AI and machine learning integration. Additionally, organizations that support research need to encourage high-quality comparative efficacy trials and sufficient data to guide therapeutic practice in epilepsy. As a result of these technologically advanced equipment and increasing drug trials, the market for epilepsy devices is anticipated to grow throughout the forecast period.

Epilepsy Devices - Key Detection Methodologies

Currently, several wearable technologies can detect seizures, collect data, and alert caregivers. Although with technological advancements, the ability to detect seizure-related alterations increases. Top trends backing this tech boom include:

Wearable devices are estimated to be the fastest-growing device type during the forecast period. Monitoring epileptic patients is crucial, as 20% of epileptics only have seizures while asleep, 40% only have seizures while awake, and 35% have seizures both when they are awake and asleep. With technologically advanced non-invasive wearable sensors, measuring accelerometry, photoplethysmography (PPG), electrodermal activity (EDA), electromyography (EMG), and other signals outside of the conventional clinical environment have become effective.

Vagus Nerve Stimulation (VNS) has emerged as the fastest-growing application category. VNS Therapy has been approved by the U.S. Food and Drug Administration (FDA) as an add-on therapy for age 4 years and above to treat drug-resistant epilepsy or refractory epilepsy. VNS has been reportedly beneficial in many patients, including the ones with posttraumatic epilepsy (PTE). PTE is a common consequence of traumatic brain injury and accounts for about 20% of symptomatic epilepsy cases.

As per estimates, Electroencephalography lead the detection and prediction devices type segment in 2021 and is expected to maintain its stronghold during the forecast period. There is growing interest in wearable or mobile EEG solutions that allow long‐term EEG monitoring in an easy‐to‐use format. Despite the availability of these new EEG solutions, their adoption is still limited in clinical practice, mainly because of the unfamiliarity of healthcare and biomedical research sectors with the technology and its application.

Strategic Initiatives and Government Approvals

Different end-users, such as homecare settings, hospitals, and clinics, are utilizing epilepsy devices. The manufacturers of epilepsy monitoring devices are likely to gain prominent business opportunities from the hospital & clinics segment owing to the rise in the use of EEG monitoring and emergency medical services.

The government authorities of several developing nations, including India and China, are focusing on developing sturdy healthcare infrastructure. As a result, operating players are expected to gain sizable growth prospects in the region during the forecast period. Owing to this, the Asia Pacific epilepsy devices market is anticipated to witness the fastest growth with a CAGR of 8.38% throughout the forecast period.

In addition, companies are also focusing on launching novel devices for children. Moreover, companies are also using organic and inorganic strategies, including mergers and acquisitions, to stay ahead of the competition. Some of these include:

In September 2022, Boston Scientific Corporation’s current-generation WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device received U.S. Food and Drug Administration (FDA) approval to expand the instructions for use labeling. The company also received FDA 510(k) clearance for the EMBOLD Fibered Detachable Coil, which reduces the blood flow rate in the peripheral vasculature.

In July 2022, Medtronic PLC received FDA 510(k) clearance for its UNiD Spine Analyzer v4.0 planning platform to leverage machine learning.

In November 2021, NeuroPace, Inc. received an Investigational Device Exemption (IDE) from the FDA to study the company’s RNS System to treat primary generalized epilepsy in patients aged 12 and above.

Way Forward

With technological advancements, epilepsy detection devices with exceptionally low false alarm rates have recently been developed. They are based on computationally intensive algorithms and employed in implanted systems for pre-surgical monitoring. Recent research has produced encouraging findings for probabilistic seizure risk projections using long-term wearable technology and electronic seizure diaries. The symptoms, mood, and cognitive function of an individual may also have predictive significance. Therefore, technological advances in non-invasive wearable sensors are anticipated to create growth opportunities for the epilepsy devices market.

FAQ:

Q1) What are the key end-users of the epilepsy devices market?

The key end-users in the epilepsy devices market include hospitals & clinics, neurology centers, homecare settings, and other end-users.

Q2) Which region leads the global epilepsy devices market?